Identification of Potent Small Molecule Inhibitors of SARS-CoV-2 Entry
Authors:
- Ronald RahaimRRRonald Rahaim
Preprint
Abstract
The severe acute respiratory syndrome coronavirus 2 responsible for COVID-19 remains a persistent threat to mankind, especially for the immunocompromised and elderly for which the vaccine may have limited effectiveness. Entry of SARS-CoV-2 requires a high affinity interaction of the viral spike protein with the cellular receptor angiotensin-converting enzyme 2. Novel mutations on the spike protein correlate with the high transmissibility of new variants of SARS-CoV-2, highlighting the need for small molecule inhibitors of virus entry into target cells. We report the identification of such inhibitors through a robust high-throughput screen testing 15,000 small molecules from unique libraries. Several leads were validated in a suite of mechanistic assays, including whole cell SARS-CoV-2 infectivity assays. The main lead compound, Calpeptin, was further characterized using SARS-CoV-1 and the novel SARS-CoV-2 variant entry assays, SARS-CoV-2 protease assays and molecular docking. This study reveals Calpeptin as a potent and specific inhibitor of SARS-CoV-2 and some variants.Keywords
All Related Versions
- Published version: SLAS Discovery, 27 (1), 8.
This publication has 71 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-CalpainJournal of Virology, 2012
- The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in miceClinical and Experimental Immunology, 2010
- Calpain inhibition preserves myocardial structure and function following myocardial infarctionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion PeptideJournal of Virology, 2008
- Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral SclerosisThe Journal of Pharmacology and Experimental Therapeutics, 2007
- RETRACTED: Spike protein of SARS‐CoV stimulates cyclooxygenase‐2 expression via both calcium‐dependent and calcium‐independent protein kinase C pathwaysThe FASEB Journal, 2007
- Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2Journal of Virology, 2004
- Improved Statistical Methods for Hit Selection in High-Throughput ScreeningSLAS Discovery, 2003
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Synthesis of a new cell penetrating calpain inhibitor (calpeptin)Biochemical and Biophysical Research Communications, 1988